1. 北京中医药大学东方医院
扫 描 看 全 文
李渊, 何明, 吴峥嵘, 等. 健脾补肾益肺方改善慢性阻塞性肺疾病大鼠气流受限的机制研究[J]. 北京中医药, 2019,38(10):999-1003.
LI Yuan, HE Ming, WU Zheng-rong, et al. Mechanism of Jianpi Bushen Yifei Formula in improving airflow limitation of rats with chronic obstructive pulmonary disease[J]. Beijing Journal of Traditional Chinese Medicine, 2019,38(10):999-1003.
李渊, 何明, 吴峥嵘, 等. 健脾补肾益肺方改善慢性阻塞性肺疾病大鼠气流受限的机制研究[J]. 北京中医药, 2019,38(10):999-1003. DOI: 10.16025/j.1674-1307.2019.10.014.
LI Yuan, HE Ming, WU Zheng-rong, et al. Mechanism of Jianpi Bushen Yifei Formula in improving airflow limitation of rats with chronic obstructive pulmonary disease[J]. Beijing Journal of Traditional Chinese Medicine, 2019,38(10):999-1003. DOI: 10.16025/j.1674-1307.2019.10.014.
目的观察健脾补肾益肺方对慢性阻塞性肺疾病(COPD)大鼠COX-2和p38MAPK蛋白的影响,研究其改善气流受限的作用机制。方法将40只Wistar大鼠随机分为正常组、模型组、COX-2抑制剂组、健脾补肾益肺方组,每组10只。模型组、COX-2抑制剂组、健脾补肾益肺方组采用气管滴注脂多糖加熏香烟方法建立COPD大鼠模型。COX-2抑制剂组给予塞来昔布[10 mg/(kg·d)]灌胃,健脾补肾益肺方组给予健脾补肾益肺方[合生药量25.2 g/(kg·d)]灌胃,正常组和模型组予同等体积的生理盐水灌胃。采用动物肺功能分析系统测定各组大鼠FEV0.3、FVC、PEF、MMEF并留取标本。采用免疫组织化学法测定各组大鼠肺组织COX-2、p38MAPK蛋白的表达量。结果模型组、COX-2抑制剂组及健脾补肾益肺方组大鼠FEV0.3、FEV0.3/FVC、PEF、MMEF较正常组显著降低(P<0.01);COX-2抑制剂组、健脾补肾益肺方组大鼠FEV0.3、FEV0.3/FVC、PEF、MMEF较模型组显著增高(P<0.01);健脾补肾益肺方组大鼠MMEF较COX-2抑制剂显著增高(P<0.05)。模型组、COX-2抑制剂组、健脾补肾益肺方组大鼠肺组织COX-2、p38MAPK的表达较正常组显著增加(P<0.01或P<0.05);COX-2抑制剂组、健脾补肾益肺方组大鼠肺组织COX-2的表达较模型组显著降低(P<0.01);健脾补肾益肺方组大鼠p38MAPK的表达较模型组、COX-2抑制剂组显著降低(P<0.05)。结论健脾补肾益肺方通过抑制COPD大鼠的COX-2表达,改善气流受限;可能与下调p38MAPK的表达有关。
Objective To investigate the effect of Jianpi Bushen Yifei Formula on improving airflow limitation of rats with chronic obstructive pulmonary disease(COPD)by detecting COX-2 and p38 MAPK protein in lung tissue,and study its mechanism.Methods 40 Wistar rats were randomly divided into 4 groups(n=10 each):normal group,model group(COPD rat model established),COX-2 inhibitor group(COPD model rats receiving celecoxib 10 mgokg-1 od-1)and Jianpi Bushen Yifei Formula group(COPD model rats receiving Jianpi Bushen Yifei Formula 25.2 gokg-1 od-1).The FEV0.3,FVC,PEF and MMEF in each group were determined.The expression level of COX-2 and p38 MAPK protein in lung tissue were detected by immunohistochemistry.Results Significant decrease of FEV0.3,FEV0.3/FVC,PEF and MMEF were found in model group,COX-2 inhibitor group and Jianpi Bushen Yifei Formula group when compared with normal group(P<0.01); FEV0.3,FEV0.3/FVC,PEF and MMEF of COX-2 inhibitor group and Jianpi Bushen Yifei Formula group were significantly improved when compared with model group(P<0.01); MMEF in Jianpi Bushen Yifei Formula group was significantly improved when compared with COX-2 inhibitor group(P<0.05).The expression of COX-2 and p38 MAPK in model group,COX-2 inhibitor group and Jianpi Bushen Yifei Formula group were significantly increased compared with normal group(P<0.01 or P<0.05); The expression of COX-2 in COX-2 inhibitor group and Jianpi Bushen Yifei Formula group were significantly decreased compared with model group(P<0.01); the expression of p38 MAPK in Jianpi Bushen Yifei Formula group were significantly lowered than model group and COX-2 inhibitor group.Conclusion Jianpi Bushen Yifei Formula can improve airflow restriction by inhibiting COX-2 expression in COPD rats,which may be related to down-regulation of p38 MAPK expression.
健脾补肾益肺方气流受限COX-2p38MAPK
Jianpi Bushen Yifei Formulaairflow limitationCOX-2p38MAPK
0
浏览量
97
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构